Univariable and multivariable analyses of NMA-haplo BMT
| Variables . | PFS . | OS . | Relapse . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | SDHR (95% CI) . | P . | HR (95% CI) . | P . | |
| Univariable* | ||||||||
| Refined DRI group | ||||||||
| Low risk | Ref | Ref | Ref | Ref | ||||
| Intermediate risk | 2.55 (1.67-3.87) | <.0001 | 2.23 (1.44-3.45) | .0004 | 3.32 (1.90-5.78) | <.0001 | 0.92 (0.49-1.74) | .80 |
| High/very high risk | 3.37 (2.10-5.41) | <.0001 | 2.86 (1.74-4.72) | .0001 | 5.29 (2.89-9.66) | <.0001 | 0.66 (0.26-1.65) | .37 |
| HCT-CI score | ||||||||
| 0 (low risk) | NT† | Ref | NT | Ref | ||||
| 1-2 (intermediate risk) | 1.11 (0.77-1.58) | .59 | 1.14 (0.55-2.34) | .73 | ||||
| ≥3 (high risk) | 1.27 (0.88-1.81) | .20 | 1.60 (0.78-3.25) | .20 | ||||
| Comorbidity-age index | ||||||||
| 0-2 (low risk) | NT† | Ref | NT | Ref | ||||
| ≥3 (high risk) | 1.17 (0.89-1.55) | .26 | 1.37 (0.81-2.34) | .24 | ||||
| Multivariable*‡ | ||||||||
| Patient age by decade§ | 1.07 (0.96-1.18) | .24 | 1.10 (0.98-1.23) | .10 | 1.03 (0.92-1.16) | .56 | 1.22 (0.96-1.54) | .10 |
| Refined DRI group | ||||||||
| Low risk | Ref | Ref | Ref | Ref | ||||
| Intermediate risk | 2.34 (1.54-3.57) | .0001 | 2.11 (1.36-3.28) | .0009 | 3.30 (1.89-5.75) | <.0001 | 0.79 (0.42-1.49) | .47 |
| High/very high risk | 3.06 (1.90-4.92) | <.0001 | 2.79 (1.69-4.60) | .0001 | 5.27 (2.90-9.61) | <.0001 | 0.58 (0.23-1.50) | .26 |
| Female donor for male patient (vs other) | 1.26 (0.95-1.68) | .11 | 1.34 (0.99-1.81) | .06 | 1.33 (0.98-1.82) | .07 | NR | |
| Patient CMV positive (vs negative) | 1.34 (1.03-1.74) | .03 | 1.31 (1.00-1.76) | .05 | NR | 1.56 (0.92-2.65) | .10 | |
| CD3+ dose ≥ 3.84 e7 /kg (vs less) | 0.77 (0.59-1.01) | .06 | NR | NR | NR | |||
| Variables . | PFS . | OS . | Relapse . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | SDHR (95% CI) . | P . | HR (95% CI) . | P . | |
| Univariable* | ||||||||
| Refined DRI group | ||||||||
| Low risk | Ref | Ref | Ref | Ref | ||||
| Intermediate risk | 2.55 (1.67-3.87) | <.0001 | 2.23 (1.44-3.45) | .0004 | 3.32 (1.90-5.78) | <.0001 | 0.92 (0.49-1.74) | .80 |
| High/very high risk | 3.37 (2.10-5.41) | <.0001 | 2.86 (1.74-4.72) | .0001 | 5.29 (2.89-9.66) | <.0001 | 0.66 (0.26-1.65) | .37 |
| HCT-CI score | ||||||||
| 0 (low risk) | NT† | Ref | NT | Ref | ||||
| 1-2 (intermediate risk) | 1.11 (0.77-1.58) | .59 | 1.14 (0.55-2.34) | .73 | ||||
| ≥3 (high risk) | 1.27 (0.88-1.81) | .20 | 1.60 (0.78-3.25) | .20 | ||||
| Comorbidity-age index | ||||||||
| 0-2 (low risk) | NT† | Ref | NT | Ref | ||||
| ≥3 (high risk) | 1.17 (0.89-1.55) | .26 | 1.37 (0.81-2.34) | .24 | ||||
| Multivariable*‡ | ||||||||
| Patient age by decade§ | 1.07 (0.96-1.18) | .24 | 1.10 (0.98-1.23) | .10 | 1.03 (0.92-1.16) | .56 | 1.22 (0.96-1.54) | .10 |
| Refined DRI group | ||||||||
| Low risk | Ref | Ref | Ref | Ref | ||||
| Intermediate risk | 2.34 (1.54-3.57) | .0001 | 2.11 (1.36-3.28) | .0009 | 3.30 (1.89-5.75) | <.0001 | 0.79 (0.42-1.49) | .47 |
| High/very high risk | 3.06 (1.90-4.92) | <.0001 | 2.79 (1.69-4.60) | .0001 | 5.27 (2.90-9.61) | <.0001 | 0.58 (0.23-1.50) | .26 |
| Female donor for male patient (vs other) | 1.26 (0.95-1.68) | .11 | 1.34 (0.99-1.81) | .06 | 1.33 (0.98-1.82) | .07 | NR | |
| Patient CMV positive (vs negative) | 1.34 (1.03-1.74) | .03 | 1.31 (1.00-1.76) | .05 | NR | 1.56 (0.92-2.65) | .10 | |
| CD3+ dose ≥ 3.84 e7 /kg (vs less) | 0.77 (0.59-1.01) | .06 | NR | NR | NR | |||
CMV, cytomegalovirus; NR, not retained in final model; NT, not tested; ref, reference category.
All models were stratified by BMT year (2002-2008 vs later).
Index is validated for NRM and OS only.
All models also considered donor age (continuous), CMV matching, and for NRM and OS, the HCT-CI score.
Increasing age by decade as a continuous variable.